CAJ | 학술논문

目的：观察盐酸埃克替尼治疗晚期非小细胞肺癌（NSCLC）的临床疗效及其影响因素。方法对2011年8月至2013年2月期间收治的57例晚期NSCLC患者进行临床随访观察，治疗方案均为口服盐酸埃克替尼125mg/次3次/日，评价其临床疗效及相关影响因素。结果全组57例患者，完全缓解（CR）3例，部分缓解（PR）21例，疾病稳定（SD）24例，疾病进展（PD）7例，客观有效率45.6%，疾病控制率87.7%，临床疗效及OS均与病理类型、性别及是否有吸烟史相关（P<0.05），仅有少数人出现皮疹（26.3%）或腹泻（12.3%），均未出现不可耐受的不良反应。结论盐酸埃克替尼治疗晚期NSCLC的临床疗效肯定，且与患者病理类型、性别及是否吸烟相关。
목적：관찰염산애극체니치료만기비소세포폐암（NSCLC）적림상료효급기영향인소。방법대2011년8월지2013년2월기간수치적57례만기NSCLC환자진행림상수방관찰，치료방안균위구복염산애극체니125mg/차3차/일，평개기림상료효급상관영향인소。결과전조57례환자，완전완해（CR）3례，부분완해（PR）21례，질병은정（SD）24례，질병진전（PD）7례，객관유효솔45.6%，질병공제솔87.7%，림상료효급OS균여병리류형、성별급시부유흡연사상관（P<0.05），부유소수인출현피진（26.3%）혹복사（12.3%），균미출현불가내수적불량반응。결론염산애극체니치료만기NSCLC적림상료효긍정，차여환자병리류형、성별급시부흡연상관。
Purpose: To evaluate the therapeutic and its influence factors of icotinib in 57 patients with advanced NSCLC. Methods: Fifty-seven patients with advanced NSCLC were enrol ed from August 2011 to February 2013. Patients were treated with icotinib (125mg,three times a day). The therapeutic effect and its influence were evaluated. Results: Among the 57 patients,3 cases were complete remission;21 cases were partial response(PR); 24 cases,stable disease(SD) and 7 cases,progression disease(PD).The objective response rate(ORR) was 45.6% and disease control rate(DCR) was 87.7%. The clinical effects and overal survival correlated with pathological type,gender and smoking(P<0.05).Only a handful of patients appeared rash(26.3%) and diarrhea (12.3%),and al of them did not appear serious adverse reactions. Conclusion: Icotinib is effective in the treatment for advanced NSCLC,and the influence factors include pathological, gender and smoking.